Trial Profile
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Golimumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms GO-SAVE
- Sponsors Centocor; Janssen Biotech
- 09 Feb 2018 Results published in The Patient - Patient-Centered Outcomes Research
- 28 Oct 2014 The number of treatment arms have been changed from 4 to 5 (open-label extension study group added) as reported by ClinicalTrials.gov record.
- 15 Jun 2012 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.